Background: The behaviour of colorectal carcinomas may depend on molecular properties of tumors. In node-positive colon cancer, we assessed the S-phase fraction (SPF) index, the vascular endothelial growth factor (VEGF) expression and the TS levels. The combined analysis of SPF/VEGF was studied for predictivity of recurrent disease, the TS quantitation was related to the efficacy of fluorouracil-based adjuvant chemotherapy.
Introduction
In recent years, adjuvant chemotherapy was found to improve survival of patients with stage III colon cancer, and 5-fluorouracil (5-FU) combined with levamisole or leucovorin have become standard medical treatments in this setting [1] . However, despite adjuvant chemotherapy, up to 40% of patients relapse and die within five years after surgery, and efforts are needed to identify and salvage this refractory population, as well as categories of high-risk patients [2] .
Moertel et al. [3] showed a relationship between the time distribution of relapses and the survival after recurrence of patients with node-positive colorectal cancer. Patients who relapsed in less than 1 year, in 1-2 years and after more than 2 years had median survival times after recurrence of 9, 15 and 20 months, respectively. The Authors proposed the existance of molecular features of colorectal tumors that may induce a more aggressive disease and resistance to fluorouracil chemotherapy.
Recent investigations have discovered innovative biological features of colorectal carcinomas which may explain the unfavourable outcome of subsets of patients. Tumor cells proliferation determined by the SPF revealed prognostic differences in patients with resected stage B2 and C colon cancer [4, 5] . The angiogenetic process sustained by the VEGF showed correlation with the metastatic potential of colon cancer and its prognosis [6, 7] . Also, the outcome of patients with colorectal cancer may depend on the sensitivity of tumor cells to fluoropyrimidines. The TS enzyme remains the main target of 5-FU, and in metastatic disease, the TS levels were found to be predictive of responsiveness to 5-FUbased chemotherapy [8] [9] [10] . Preliminary experiences suggest that the TS levels may predict the efficacy of adjuvant chemotherapy [11] .
These data prompetd us to conduct a retrospective analysis of patients with node-positive colon cancer who had received or not 5-FU-based adjuvant chemotherapy. In their tumors we evaluated the SPF, the VEGF expression and the TS levels. The combined analysis of SPF and VEGF was performed to assess whether a specific molecular profile may be predictive of recurrent disease. Furthermore, we investigated the relationship between TS levels and the efficacy of adjuvant chemotherapy with 5-FU.
Patients and methods

Human samples and clinicopathologic data
In our retrospective analysis, the study population consisted of consecutive patients who underwent radical surgery for stage III colon cancer between 1987 and 1995. Eligible patients between 1987 and 1989 did not receive adjuvant chemotherapy according to the state-of-theart of that period, and they served as controls. Eligible patients bewteen 1990 and 1995 had received fluorouracil-based adjuvant chemotherapy. Other inclusion criteria consisted of sufficient archivial tissue for the analyses and adequate follow-up information. Patients had to be observed for five years after surgery at least. The follow-up consisted of interim history, physical examination, hematologic studies, carcinoembryonic antigen levels and diagnostic imaging (chest X-ray, abdominal ultrasonography) every four months in the first year, and every six months in the second through fifth years. Patients had barium enema or a colonoscopic examination six months after surgery and subsequently every 12 months. Abdominal and pelvic computed tomographic scan was performed for corroborative evidence of relapse. The recurrences of colon carcinoma had to be proven by cytology biopsy or surgery and they were categorized as early, if occurred within 12 months after surgery or late, if occured 13 months or more.
The analysis was carried out on the primary tumor and all the cases were reviewed by the pathologist. The selected blocks were those in which mucosa. invasive edge and viable tumor were present. The study was performed in a blind fashion, so that patients' outcome was unknown by the investigators performing SPF measurements (M. Valentini and C. Grianti), VEGF and TS analyses (M. P. Staccioli and C. Rossi).
Flow cytometric analysis
The method is fully described in a previous study [4] , In brief, flow cytometric analysis was carried out with an Epics Profile II flow cytometcr (Coulter Electronics Hialeah. Florida), equipped with 1.5-Watt argon ion laser. Histograms were recorded for a minimum of 25,000 nuclei (excluding internal standard) at flow rates no greater than 30-50 events/second. Electronic gating of the light scanner signal was used to exclude cellular debris and aggregates form data acquisition. The SPF, determined as the area under the curve between the G0-G1 and G2-M peaks, was calculated using Multicycle Cell Cycle Analysis Software program. The 20% mean SPF observed in our series was considered to discriminate cases with high or low SPF. This value is in line with data from other reported series [4, 5] 
Vascular endothelial growth factor analysis
Four-micrometer-thick tissue section of the primary tumor were deparafflned in xylene and rehydrated in a graded ethanol series. Specimens were placed in a Coplin jar containing citric buffer and heated 3x5 minutes in a microwave processor. Subsequently, the sections were left in the Coplin jar at room temperature for 20 minutes. After an incubation in 3% hydrogen-peroxide for 8 minutes, specimens were covered with normal swine serum for 10 minutes to reduce nonspecific staining and incubated with a 1:20 dilution of rabbit policlonal antibody for VEGF (Biogenex, San Ramon, California) at room temperature for 30 minutes. The sections were washed and incubated with a 1: 50 dilution of biotinylated swine anti-rabbit immunoglobulin G at room temperature for 20 minutes and then covered with a 1:100 dilution of streptavidin-biotin-peroxidase complex at room temperature for 20 minutes. The antibody was localized with 3,3'-diaminobenzidine tetrahydroclonde. Tissue sections were counterstained with light haematoxihn, dehydrated with ethanol and mounted under a coverslip.
The staining results were interpreted independently by two investigators, and for each case, the entire section was examined on highpower fields. The antibody showed cytoplasmatic localization of the VEGF protein and only clearly immunoreactive cells were recorded as VEGF positive. The expression of the VEGF was scored as percentage of immunoreactive cells on a total of 1000 neoplastic cells (quantitative analysis). Immunoreactivity was graded as follows: positive, more than 10% of tumor cells stained; negative, absent or less than 10% of tumor cells stained (Figure 1 ) [12] Furthermore, a qualitative intensity of staining was performed using a scale of 0-3+, with 0 representing no detectable staining and 3+ the strongest staining [13] .
Thymidylate synthase analysis
TS protein expression was evaluated by the avidin-biotin complex immunohistochemical technique using a mouse monoclonal antibody to recombinant human TS enzyme (NeoMarkers, Union City, California). Two-micrometer-thick tissue sections were cut, deparaffinized in xylene, rehydrated with graded ethanol. and immersed in trisbuffered saline. Endogenous peroxidase activity was quenched with 3% hydrogen peroxide in distilled water for 15 minutes. The slides were heated in a microwave oven at 300 Watt for 10 minutes, cooled, and stored in tris-buffered saline at pH 7.6. To block nonspecific binding of the primary antibody, a normal rabbit serum (DAKO X901; Dakopatts Co, Glostrup, Denmark) dilution in tris-buffered saline was used for 20 minutes. After the blocking solution was removed, the TS antibody (2 mg/ml) was applied for 60 minutes in a humidified chamber at room temperature. Negative control studies were performed without applying the primary antibody. The sections were then incubated with biotinconjugated swine anti-rabbit immunoglobulins for 20 minutes (DAKO-E353), followed by the avidin-biotinylated peroxidase complex for 30 minutes. After the color reaction product was developed with a freshly prepared diaminobenzidine chromogen solution for five minutes, the sections were counterstained with light hematoxylin for one minute, dehydrated in a series of ethanols, cleared in xylene, and mounted with glass coverslips. Sections known to stain positively were included in each run as positive controls. Only tumor cells with cytoplasmic staining were counted as positive. TS expression was quantitated using a visual grading system based on the intensity of staining and classified into five groups from 0 (undetectable staining) to 4 (very high intensity of staining). For the purpose of correlation with clinical data, intensity levels 0-2 were grouped together and considered low expression and levels 3 and 4 were considered high expression (Figure 1 ). The agreement in TS evaluation between the two observers was greater than 90%. In the four cases of disagreement, a final score was determined by consensus after re-examination. When heterogenous TS levels were found within a tumor, the highest degree of TS expression was taken to define the status.
Statistical analysis
The survival time after recurrence was calculated from the data of confirmed relapse to the time of death and the Kaplan-Meier method was adopted to estimate survival curves. Differences between survival curves were studied by means of the log-rank test. Contingency tables were analyzed by the Fisher's exact test or the Chi-square test as appropriate. All the values were two-sided and statistical significance was defined as P < 0.05. 
Results
Characteristics of patients
According to the inclusion criteria, tumors of 150 out of 154 consecutive patients were analyzed. Four cases were excluded (2.6%) because of insufficient follow-up information (three cases) or unassessable archival tissue (one case). Fifty patients were untreated while 100 patients had received adjuvant chemotherapy with the fluorouracillevamisole combination (50 patients) or the fluorouracilleucovorin combination (50 patients). The distribution of clinicopathologic variables is reported in Table 1 and they are comparable between the three groups (P > 0.05).
There were 26 relapses (52%) in the 50 control patients and 30 relapses (30%) in the 100 patients treated with adjuvant chemotherapy. The median survival time after recurrence was 8.5 months in the 28 patients with early relapse and 15 months in the 28 patients with late relapse (/> < 0.01).
SPFand VEGF analysis
The SPF was low in 83 cases (55%) and high in 67 cases (45%), the VEGF resulted positive in 62 cases (41%) and (32%) had high SPF/VEGF positive tumors and 69 patients (46%) had low SPF/VEGF negative tumors (P < 0.0001). The distribution of the 94 disease-free patients according to the SPF/VEGF profile is reported in Table 3 , in this analysis, a significant higher proportion of patients (73.4%) showed VEGF negative/low SPF tumors (P < 0.0001). None of the fifty-six patients with recurrent disease had VEGF negative/low SPF tumors (Table 4) and twenty-seven patients (48.2%) showed VEGF positive/high SPF tumors (P < 0.01). In Table 5 is summarized the time distribution of relapses according to the SPF/VEGF profile: patients with VEGF positive/high SPF tumors showed early recurrences, while late relapses occurred in patients whose tumors had either high SPF or VEGF positivity (P < 0.001).
These data suggest the existence of three subgroups of patients; those with VEGF positive/high SPF tumors, early relapse and short survival time after recurrence (high-risk), those with either VEGF positive or high SPF tumors, late relapse and longer survival time after recurrence (intermediate-risk) and those with VEGF negative/ low SPF tumors who did not relapse (low-risk).
rS analysis
In the 100 patients who received adjuvant chemotherapy theTS expression was positive and negative in 48 and 52 cases, respectively. In spite of adjuvant chemotherapy 30 patients relapsed (30%) and 26 of them (86.6%) had TS-positive tumors. In the 70 disease-free patients, 48 patients (68.5%) showed TS-negative tumors (Table 6) .
Also, the association between the TS status and the efficacy of adjuvant chemotherapy was evident in the subset analysis of the 48 high-risk patients (high SPF/ VEGF positive tumor). In the control group, all the 16 Table 6 . Relationship between the TS status and the outcome of 100 patients treated with adjuvant chemotherapy (P < 0.001). Table 7 . Relationship between the TS status and the outcome of 32 high-risk patients treated with adjuvant chemotherapy (P < 0.001). patients with high-risk tumors had early relapse. In the 100 patients who received adjuvant chemotherapy, the 21 high-risk patients with TS-negative tumors remained disease-free, whilst the 11 high-risk patients with TSpositive tumors showed early relapse (Table 7) .
Relapsed
No association was detected between theTS status and the VEGF expression or the SPF index (data not shown).
Discussion
A growing burden of investigations in cancer biology aims at the identification of molecular properties of tumors that may determine their natural history and their responsiveness or resistance to chemotherapy. In the present study, evidence is supported that node-positive colon cancer constitutes a heterogenous disease. The biological profile determined by the combined analysis of VEGF and SPF may explain the higher aggressiveness of some of these tumors. TS quantitation identified subsets of patients unlikely to benefit from fluorouracilbased adjuvant chemotherapy.
An increasing number of experimental data suggest that tumor progression and recurrence may depend on the VEGF expession [13] [14] [15] [16] [17] [18] [19] . In breast cancer, the VEGF expression defined high and low-risk subgroups of patients [18] , and it was associated to the occurrence of early relapse [19] . A multipeak pattern of relapse has been described in operable breast cancer, with early metastases occuring 12-24 months from surgery [20] . In this study, late relapsing patients seemed to have lower benefit from adjuvant chemotherapy, which showed the highest efficacy to prevent early recurrences. In lung carcinomas, the combined analysis of cell proliferation and VEGF expression demonstrated the biological heterogeneity of these tumors which translated into different clinical behaviours [21] . In this experience, patients whose tumors showed high proliferation and VEGF expression had an increased incidence of metastases and shorter survival.
The coexistence of high proliferative activity and VEGF up-regulation has been described in several solid neoplasms [22] [23] [24] [25] [26] . This phenomenon may be related to an autocrine growth-stimulating function of the VEGF itself [21] ; VEGF expression was found to enhance the metastatic power of cancer by accelerating proliferative activity in the primary tumor and after reaching the target organ [25] . Also, genetic abnormalities may cause a simultaneous effect on tumor cell proliferation and angiogenesis. Mutations of the Ras oncogenes often occur in colorectal cancer and they are involved in tumor growth not only by a direct effect on cell proliferation, but also facilitating angiogenesis by the VEGF expression [27] [28] [29] .
So far, the significance of TS quantitation has been documented in metastatic colorectal cancer and it was found to be predictive of resistance to palliative fluorouracil-based chemotherapy [8] [9] [10] . In a retrospective analysis of TS in rectal cancer, adjuvant chemotherapy improved the disease-free and the overall survival of patients withTS overexpressing tumors [11] . Our experience shows that 5-FU-based adjuvant chemotherapy reduces the frequency of early relapses in high-risk patients, but its efficacy depends on the TS levels of expression. In fact, TS-induced resistance to adjuvant fluoropyrimidines may account for treatment failures, and this study provides evidence on this issue.
Basing on the biological features of colon carcinomas, it seems possible to hypothesize innovative treatment strategies in the post-surgical management of patients with node-positive disease.
Adjuvant chemotherapy might be unnecessary to low-risk patients, conversely, high-risk patients deserve systemic treatment and it could be tailored considering the results of the TS analysis. Patients with TS overexpressing tumors may not be good candidates for adjuvant fluorouracil and they might have a better outcome if treated with other chemotherapeutic agents with alternative mechanisms of action. Recently, new drugs such as irinotecan and oxaliplatin have shown activity in colorectal cancer. In a recent phase II trial, Andre et al. [30] have demonstrated that the addition of oxaliplatin to fluorouracil resulted in enhanced activity against metastatic disease, thus representing a chemotherapeutic strategy to overcome resistance to fluorouracil. This combination exploits two different cytotoxic pathways and it works in a heterogeneous population of cancer cells with different levels of TS expression. In the future, TS expression could be considered before randomization in adjuvant chemotherapy trials, and alternative chemotherapeutic combinations could be offered to patients unlikely to respond to fluorouracil alone.
In our experience, 50% of recurrences were beyond
